Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,055 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy: A Multicenter Cohort Study.
Blant JC, De Rossi NN, Gold R, Maurousset A, Kraemer M, Romero-Pinel L, Misu T, Ouallet JC, Pallix Guyot M, Gerevini S, Bakirtzis C, Piñar Morales R, Vlad B, Karypidis P, Moisset X, Derfuss TJ, Jelcic I, Martin-Blondel G, Ayzenberg I, McGraw C, Laplaud DA, Du Pasquier RA, Bernard-Valnet R; for CORPUS and Italian study groups. Blant JC, et al. Among authors: gold r. Neurol Neuroimmunol Neuroinflamm. 2024 Sep;11(5):e200281. doi: 10.1212/NXI.0000000000200281. Epub 2024 Jul 11. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 38991170 Free PMC article.
Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.
Haghikia A, Perrech M, Pula B, Ruhrmann S, Potthoff A, Brockmeyer NH, Goelz S, Wiendl H, Lindå H, Ziemssen T, Baranzini SE, Käll TB, Bengel D, Olsson T, Gold R, Chan A. Haghikia A, et al. Among authors: gold r. PLoS One. 2011 Apr 20;6(4):e18506. doi: 10.1371/journal.pone.0018506. PLoS One. 2011. PMID: 21533133 Free PMC article. Clinical Trial.
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J. Kappos L, et al. Among authors: gold r. Lancet Neurol. 2011 Aug;10(8):745-58. doi: 10.1016/S1474-4422(11)70149-1. Lancet Neurol. 2011. PMID: 21777829 Free article. Review.
Immunological and clinical consequences of treating a patient with natalizumab.
Schwab N, Höhn KG, Schneider-Hohendorf T, Metz I, Stenner MP, Jilek S, Du Pasquier RA, Gold R, Meuth SG, Ransohoff RM, Brück W, Wiendl H. Schwab N, et al. Among authors: gold r. Mult Scler. 2012 Mar;18(3):335-44. doi: 10.1177/1352458511421919. Epub 2011 Sep 9. Mult Scler. 2012. PMID: 21908480
2,055 results